Flexion Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$11.3M
Doctors Paid
10,183
Transactions
37,550
2020 Total
$2.1M
Payment Breakdown by Category
Research$6.6M (58.2%)
Consulting$1.8M (15.8%)
Food & Beverage$867,939 (7.7%)
Travel$349,908 (3.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.6M | 183 | 58.2% |
| Consulting Fee | $1.8M | 502 | 15.8% |
| Honoraria | $1.5M | 613 | 13.5% |
| Food and Beverage | $867,939 | 34,655 | 7.7% |
| Travel and Lodging | $349,908 | 976 | 3.1% |
| Grant | $100,000 | 2 | 0.9% |
| Space rental or facility fees (teaching hospital only) | $91,271 | 29 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,942 | 246 | 0.1% |
| Education | $4,294 | 344 | 0.0% |
Payments by Type
Research
$6.6M
183 transactions
General
$4.7M
37,367 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| An Open-Label Study to Evaluate the Effect of the Administration of FX006 on Synovial Inflammation in Patients with Osteoarthritis of the Knee | $2.6M | 0 | 22 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Hip Osteoarthritis | $1.1M | 0 | 58 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis | $661,744 | 0 | 36 |
| A Randomized, Open-label Study Comparing the Systemic Exposure to Triamcinolone Acetonide Following a Single Intra-articular Dose of Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension) in Patients with Osteoarthritis of the Shoulder (Glenohumeral Joint) or Hip | $386,201 | 0 | 7 |
| An Open-label Study to Assess the Safety of Repeat Administration of FX006 to Patients with Osteoarthritis of the Knee | $379,060 | 0 | 19 |
| Study to Evaluate the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee | $322,211 | 0 | 3 |
| Success of Long-acting Anti-inflammatories after anterior cruciate ligament and Meniscal injury SLAM | $194,996 | 1 | 1 |
| Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip | $184,942 | 0 | 11 |
| Benefits of IA Injections | $116,025 | 0 | 2 |
| A study of the Effect of Intraarticular Corticosteroid on Metabolic Syndrome Biomarkers A Pilot Feasibility Study | $109,806 | 1 | 1 |
| Zilretta vs. TAcs | $101,600 | 0 | 1 |
| Rotator Cuff | $82,453 | 0 | 1 |
| Effect of ZILRETTA Injection on Neuromuscular Function, Gait Biomechanics and Physical Performance | $74,012 | 0 | 1 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Glenohumeral Osteoarthritis or Shoulder | $57,625 | 0 | 10 |
| Success of Long-acting Anti-inflammatories after anterior cruciate ligament and Meniscal injury (SLAM) | $48,749 | 0 | 1 |
| An open-label pilot study of the effect of intra-articular bilateral knee injections of Zilretta (FX006) on OARSI recommended physical performance measures in adults with knee osteoarthritis. | $45,156 | 0 | 1 |
| Patient- and Physician-Perceived Barriers to and Benefits of Intraarticular Injections for Osteoarthritis: A Qualitative Study | $29,006 | 0 | 1 |
| A study of the Effect of Intraarticular Corticosteroid on Metabolic Syndrome Biomarkers (A Pilot / Feasibility Study) | $27,452 | 0 | 1 |
| A Stratified Investigation of a Single Injection of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) for Symptomatic Relief in Patients with Idiopathic Adhesive Capsulitis of the Shoulder. | $24,529 | 0 | 1 |
| A Randomized, Open-label, Parallel Group Study in Patients with Bilateral Knee Osteoarthritis Comparing the Systemic Exposure of Triamcinolone Acetonide Following Administration into Both Knees of either Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension) | $20,687 | 0 | 3 |
| Zilretta for Shoulder IAC | $20,441 | 0 | 1 |
| Study to assess the safety and efficacy of FX006 administered to patients with greater trochanteric bursitis | $15,439 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 7
| Doctor | Specialty | Location | Total | 2020 |
|---|---|---|---|---|
| Dr. Gregory Martin, M.d, M.D | Specialist | Boynton Beach, FL | $1,426 | $0 |
| Arthur Malkani, M.d, M.D | Orthopaedic Surgery | Louisville, KY | $1,414 | $0 |
| Eric Mccarty, Md, MD | Sports Medicine | Aurora, CO | $1,406 | $0 |
| Adolph Lombardi, Md, MD | Orthopaedic Surgery | New Albany, OH | $1,400 | $0 |
| Joy Schechtman, Do, DO | Rheumatology | Peoria, AZ | $1,391 | $0 |
| Jasper Petrucci, M.d, M.D | Orthopaedic Surgery | Geneva, IL | $1,386 | $0 |
| Christopher Boone, M.d, M.D | Orthopaedic Trauma | Bellevue, WA | $1,372 | $0 |
| Richard Roseff, Md, MD | Rheumatology | Danbury, CT | $1,325 | $0 |
| Dr. Amon Ferry, Md, MD | Orthopaedic Surgery | Scottsdale, AZ | $1,210 | $0 |
| Mr. Kieran Cody, M.d, M.D | Specialist | Doylestown, PA | $1,200 | $0 |
| Mr. Lawrence Kempf, Md, MD | Internal Medicine | New York, NY | $1,171 | $0 |
| William Kurtz, Md, MD | Adult Reconstructive Orthopaedic Surgery | Brentwood, TN | $1,118 | $0 |
| Dr. Lisa Persyn, Md, MD | Physical Medicine & Rehabilitation | Austin, TX | $1,027 | $0 |
| Steven Cohen, M.d, M.D | Anesthesiology | Chicago, IL | $1,000 | $0 |
| Nicholas Sgaglione, Md, MD | Orthopaedic Surgery | Great Neck, NY | $993.95 | $0 |
| Laith Jazrawi, M.d, M.D | Orthopaedic Surgery | New York, NY | $981.74 | $0 |
| Dr. Frank Armocida, M.d, M.D | Orthopaedic Surgery | Greer, SC | $980.96 | $0 |
| Richard Winder, Md, MD | Orthopaedic Surgery | Las Vegas, NV | $957.29 | $0 |
| Dr. Brian Cole, M.d, M.D | Sports Medicine | Chicago, IL | $938.00 | $0 |
| Kurt Spindler, Md, MD | Orthopaedic Surgery | Garfiled Heights, OH | $930.51 | $0 |
| Peter Sharkey, M.d, M.D | Adult Reconstructive Orthopaedic Surgery | King Of Prussia, PA | $917.80 | $0 |
| Robert Stanton, Md, MD | Orthopaedic Surgery | Fairfield, CT | $912.17 | $0 |
| Dr. Christianne Yung, Md, MD | Rheumatology | Henderson, NV | $891.51 | $0 |
| Erik Stark, Md, MD | Orthopaedic Surgery | Oceanside, CA | $858.49 | $0 |
| Dr. Scott Parry, M.d, M.D | Orthopaedic Surgery | St George, UT | $858.16 | $0 |
About Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc. has made $11.3M in payments to 10,183 healthcare providers, recorded across 37,550 transactions in the CMS Open Payments database. In 2020, the company paid $2.1M. The top product by payment volume is Zilretta ($10.0M).
Payments were distributed across 117 medical specialties. The top specialty by payment amount is Orthopaedic Surgery ($2.3M to 3,632 doctors).
Payment categories include: Food & Beverage ($867,939), Consulting ($1.8M), Research ($6.6M), Travel & Lodging ($349,908).
Flexion Therapeutics, Inc. is associated with 1 products in the CMS Open Payments database.